Navigation Links
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
Date:7/30/2009

crease in basic and diluted net loss per share for the second quarter of 2009 and 2008, respectively.

For the six months ended June 30, 2009, Anadys reported a net loss of $15.3 million, compared to $14.5 million for the same period last year. Basic and diluted net loss per common share was $0.51 for the six months ended June 30, 2009 and 2008.

Operational Highlights

  • Closed Registered Direct Financing. In early June, Anadys closed a "registered direct" offering through the sale of units to institutional investors, with each unit consisting of one share of common stock and a warrant to purchase 0.35 of a share of common stock. $17.5 million in gross proceeds were raised, with net proceeds of approximately $16.0 million, after deducting placement agent fees and estimated offering expenses. Proceeds from the transaction are being used to further the development of ANA598, as well as for other general corporate purposes.
  • Future Operations to Focus on Development of ANA598. In June, Anadys initiated a strategic restructuring to focus its operations on the continued development of ANA598, in particular a Phase II study in combination with pegylated interferon-alpha and ribavirin. The restructuring included a reduction in Anadys' workforce expected to generate annual savings of $4 to $5 million, while retaining the clinical development infrastructure required to conduct the Phase II study of ANA598, key capabilities directed toward pharmaceutical development and next generation non-nucleosides, and a streamlined administrative staff. Also included in the restructuring is an expected reduction in annual facility expense of approximately $1.8M associated with our completed move to a smaller facility.

Development Program Highlights

ANA598

ANA598 is the Company's non-nucleoside H
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
2. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
3. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
4. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
5. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
6. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
7. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
8. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
9. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
10. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
11. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... ITRA Global, one of the largest organizations dedicated ... has further expanded its global reach with the affiliation ... Australia, reports Mylinda Vick, CCIM, Chairman of the ITRA ... ACORPP (Australian Corporate Property and Projects) , is a ... to a wide range of clients in the private ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that its ... M1 in raw commingled milk is the first lateral ... peer reviewed report of the validation by Technology and ... Fisheries Research (ILVO-T&V) has been published by the Taylor ... toxic aflatoxin and a known carcinogen, can be passed ...
(Date:12/19/2014)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today ... privately held company based in Redwood ... big data platform for centralized management and processing ... on-market Genomic Management Solution, Bina-GMS 1 , empowers ... and scalable analyses to maximize the value of ...
(Date:12/19/2014)... DUBLIN , Dec. 19, 2014 Research ... announced the addition of the "Technology Innovations ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... Innovations in Smart Fabrics" offers a detailed assessment ... Key Findings: 1. ...
Breaking Biology Technology:ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Technology Innovations in Smart Fabrics (Technical Insights) 2
... New Service Helps Customers to Treat More Patients, ... ARAY ), a global leader in the ... begin offering a treatment planning,service to new and ... centers to access a dedicated team of remote ...
... Quintiles,Transnational Corp. today announced the completion of ... company,s continued,growth under the leadership of founder and ... management team. Gillings and global private,investment firms Bain ... in Quintiles, with 3i also becoming a significant ...
... Ind., Jan. 23 Zimmer Holdings, Inc.,(NYSE: ZMH ... announced,today it will be participating in the Wachovia Securities ... 10:15 a.m. Eastern Time., A live webcast of ... at http://investor.zimmer.com . The webcast will,be archived for ...
Cached Biology Technology:Accuray Announces New Treatment Planning Service Offering 2Accuray Announces New Treatment Planning Service Offering 3Accuray Announces New Treatment Planning Service Offering 4Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 2Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 3
(Date:12/10/2014)... DUBLIN , Dec. 08, 2014 Research ... announced the addition of the "Biometrics Market ... http://photos.prnewswire.com/prnh/20130307/600769 ... for projects such as rural banking and upgradation ... major trends witnessed in the market. Besides the ...
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... New York College, and one of the most prolific ... signals that are transmitted from Smartphones to third party ... Smartphones and has one of the earliest known patents ... its usage in the military, child care, elder care ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... Athens, Ga. Companion animals that have a long-term need ... top-selling antiplatelet drug marketed to humans: clopidogrel, commonly known ... Georgia College of Veterinary Medicine have found ,that clopidogrel may ... long-term anticoagulant therapy. In addition, it may offer a ...
... Associate Professor at The City College of New York (CCNY), have ... water so that it can be scooped up like the fat ... soup. The agent could potentially be used to recover oil lost ... Professor John said. In the laboratory, Professor John and colleagues ...
... in cities, disposing of garbage and recycling anything that ... city and cell, health problems can arise when the ... of Michigan cell biologist Haoxing Xu and colleagues reveals ... recycling center, the lysosome, functions. These insights, which may ...
Cached Biology News:Plavix may be treatment for dogs at risk of thromboembolic disease 2Opening the gate to the cell's recycling center 2